Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Creation of immune ‘stealth’ genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1

Gene Therapy volume 10, pages 2020–2028 (2003) Cite this article

Abstract

A major obstacle in gene-therapy protocols is T-cell-mediated destruction of transgene-expressing cells. Therefore new approaches are needed to prevent rapid clearance of transduced cells. We exploited the Gly-Ala repeat (GAr) domain of the Epstein–Barr virus nuclear antigen-1, since the GAr prevents cytotoxic T-lymphocyte-epitope generation. Here we show that three different enzymes (viz. the E. coli LacZ gene encoded β-galactosidase, firefly luciferase, and HSV1 thymidine kinase) fused with the GAr retained their function. Moreover, linking GAr with β-galactosidase successfully prevented recognition of GAr-LacZ-expressing cells by β-galactosidase-specific CTL. Nonetheless, vaccination with a GAr-LacZ adenovirus or with an allogeneic cell line expressing GAr-LacZ resulted in the induction of β-gal-specific CTL. This demonstrates that the GAr domain does not inhibit crosspresentation of antigens, but only affects breakdown of endogenously synthesized proteins. These data demonstrate how the GAr domain can be exploited to create immuno‘stealth’ genes by hiding transgene products from CTL-mediated immune attack.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
The alternative text for this image may have been generated using AI.
Figure 2
The alternative text for this image may have been generated using AI.
Figure 3
The alternative text for this image may have been generated using AI.
Figure 4
The alternative text for this image may have been generated using AI.
Figure 5
The alternative text for this image may have been generated using AI.
Figure 6
The alternative text for this image may have been generated using AI.

Similar content being viewed by others

References

  1. Christ M et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol Lett 1997; 57: 19–25.

    Article  CAS  PubMed  Google Scholar 

  2. Geutskens SB et al. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Therapy 2000; 7: 1410–1416.

    Article  CAS  PubMed  Google Scholar 

  3. Michou AI et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Therapy 1997; 4: 473–482.

    Article  CAS  PubMed  Google Scholar 

  4. Yang Y, Ertl HC, Wilson JM . MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433–442.

    Article  CAS  PubMed  Google Scholar 

  5. Sullivan NJ et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408: 605–609.

    Article  CAS  PubMed  Google Scholar 

  6. Ulmer JB et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745–1749.

    Article  CAS  PubMed  Google Scholar 

  7. Cordier L et al. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Therapy 1995; 2: 16–21.

    CAS  PubMed  Google Scholar 

  8. Toes RE et al. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 1997; 94: 14660–14665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kay MA, Glorioso JC, Naldini L . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33–40.

    Article  CAS  PubMed  Google Scholar 

  10. Molinier-Frenkel V et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000; 74: 7678–7682.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Abina MA et al. LacZ gene transfer into tumor cells abrogates tumorigenicity and protects mice against the development of further tumors. Gene Therapy 1996; 3: 212–216.

    CAS  PubMed  Google Scholar 

  12. Cordier L et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001; 12: 205–215.

    Article  CAS  PubMed  Google Scholar 

  13. Jooss K et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212–4223.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Juillard V et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995; 25: 3467–3473.

    Article  CAS  PubMed  Google Scholar 

  15. Yang Y, Su Q, Wilson JM . Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996; 70: 7209–7212.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Yang Y, Wilson JM . Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+CTLs in vivo. J Immunol 1995; 155: 2564–2570.

    CAS  PubMed  Google Scholar 

  17. Ye X et al. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. Gene Therapy 2000; 7: 1761–1767.

    Article  CAS  PubMed  Google Scholar 

  18. Zsengeller ZK et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 1995; 6: 457–467.

    Article  CAS  PubMed  Google Scholar 

  19. Kolls JK et al. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 489–497.

    Article  CAS  PubMed  Google Scholar 

  20. Chirmule N et al. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. J Immunol 1999; 163: 448–455.

    CAS  PubMed  Google Scholar 

  21. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407–4411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yang Y et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004–2015.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Yang Y et al. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet 1996; 5: 1703–1712.

    Article  CAS  PubMed  Google Scholar 

  24. Latta-Mahieu M et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 2002; 13: 1611–1620.

    Article  CAS  PubMed  Google Scholar 

  25. Thomis DC et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001; 97: 1249–1257.

    Article  CAS  PubMed  Google Scholar 

  26. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191–197.

    Article  CAS  PubMed  Google Scholar 

  27. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137–144.

    PubMed  Google Scholar 

  28. Yang Y et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370–6377.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Wiertz EJ, Mukherjee S, Ploegh HL . Viruses use stealth technology to escape from the host immune system. Mol Med Today 1997; 3: 116–123.

    Article  CAS  PubMed  Google Scholar 

  30. Ploegh HL . Viral strategies of immune evasion. Science 1998; 280: 248–253.

    Article  CAS  PubMed  Google Scholar 

  31. Khanna R et al. Localization of Epstein–Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992; 176: 169–176.

    Article  CAS  PubMed  Google Scholar 

  32. Khanna R et al. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein–Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 1995; 214: 633–637.

    Article  CAS  PubMed  Google Scholar 

  33. Munz C et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein–Barr virus nuclear antigen EBNA1. J Exp Med 2000; 191: 1649–1660.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Blake N et al. Human CD8+T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997; 7: 791–802.

    Article  CAS  PubMed  Google Scholar 

  35. Blake N et al. The importance of exogenous antigen in priming the human CD8+T cell response: lessons from the EBV nuclear antigen EBNA1. J Immunol 2000; 165: 7078–7087.

    Article  CAS  PubMed  Google Scholar 

  36. Rickinson AB, Moss DJ . Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection. Annu Rev Immunol 1997; 15: 405–431.

    Article  CAS  PubMed  Google Scholar 

  37. Levitskaya J et al. Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. Nature 1995; 375: 685–688.

    Article  CAS  PubMed  Google Scholar 

  38. Levitskaya J et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997; 94: 12616–12621.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Gavin MA et al. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol 1993; 151: 3971–3980.

    CAS  PubMed  Google Scholar 

  40. Toes RE et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996; 56: 3782–3787.

    CAS  PubMed  Google Scholar 

  41. Sharipo A et al. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat Med 1998; 4: 939–944.

    Article  CAS  PubMed  Google Scholar 

  42. Sharipo A et al. cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition. FEBS Lett 2001; 499: 137–142.

    Article  CAS  PubMed  Google Scholar 

  43. Dantuma NP et al. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein–Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci USA 2000; 97: 8381–8385.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Tellam J et al. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+T cell recognition. J Biol Chem 2001; 276: 33353–33360.

    Article  CAS  PubMed  Google Scholar 

  45. Heessen S et al. Functional p53 chimeras containing the Epstein–Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proc Natl Acad Sci USA 2002; 99: 1532–1537.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Bevan MJ . Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976; 143: 1283–1288.

    Article  CAS  PubMed  Google Scholar 

  47. Sigal LJ et al. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398: 77–80.

    Article  CAS  PubMed  Google Scholar 

  48. Benihoud K, Yeh P, Perricaudet M . Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999; 10: 440–447.

    Article  CAS  PubMed  Google Scholar 

  49. Price J, Turner D, Cepko C . Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 1987; 84: 156–160.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. He TC et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509–2514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Fallaux FJ et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215–222.

    Article  CAS  PubMed  Google Scholar 

  52. Fallaux FJ et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9: 1909–1917.

    Article  CAS  PubMed  Google Scholar 

  53. Pietersen AM et al. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Therapy 1999; 6: 882–892.

    Article  CAS  PubMed  Google Scholar 

  54. de Roos WK et al. Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver. Gene Therapy 1997; 4: 55–62.

    Article  CAS  PubMed  Google Scholar 

  55. Hoeben RC et al. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J Virol 1991; 65: 904–912.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. van der Eb MM et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Therapy 1998; 5: 451–458.

    Article  CAS  PubMed  Google Scholar 

  57. Hoerr I et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30: 1–7.

    Article  CAS  PubMed  Google Scholar 

  58. Toes RE et al. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol 1995; 154: 3396–3405.

    CAS  PubMed  Google Scholar 

  59. Chalmers D et al. Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther 2001; 4: 146–148.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The expert technical support of Ed Barthen is greatly appreciated. The research of REM Toes has been made possible by the Royal Academy of Arts and Sciences. The work was supported in part by Netherlands Organization for Scientific Research (program Grant 901-07-097).

Author information

Author notes

  1. M Ossevoort and B M J Visser: The first two authors contributed equally to the work presented in the manuscript and both should be regarded ‘first author’.

Authors and Affiliations

  1. Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands

    M Ossevoort, D J M van den Wollenberg & R C Hoeben

  2. Department of Immunohematology and Blood Bank, Leiden University Medical Center, Leiden, The Netherlands

    B M J Visser, E I H van der Voort, R Offringa, C J M Melief & R E M Toes

  3. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

    E I H van der Voort & R E M Toes

Authors
  1. M Ossevoort
    View author publications

    Search author on:PubMed Google Scholar

  2. B M J Visser
    View author publications

    Search author on:PubMed Google Scholar

  3. D J M van den Wollenberg
    View author publications

    Search author on:PubMed Google Scholar

  4. E I H van der Voort
    View author publications

    Search author on:PubMed Google Scholar

  5. R Offringa
    View author publications

    Search author on:PubMed Google Scholar

  6. C J M Melief
    View author publications

    Search author on:PubMed Google Scholar

  7. R E M Toes
    View author publications

    Search author on:PubMed Google Scholar

  8. R C Hoeben
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ossevoort, M., Visser, B., Wollenberg, D. et al. Creation of immune ‘stealth’ genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther 10, 2020–2028 (2003). https://doi.org/10.1038/sj.gt.3302098

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.gt.3302098

Keywords

This article is cited by

Search

Advanced search

Quick links